Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials.

Published

Journal Article

Pegloticase is approved in the US for treatment of refractory chronic gout. Since chronic kidney disease (CKD) is common in these patients, we conducted a post-hoc analysis of 2 replicate phase 3 trials and the subsequent open-label extension study to determine the effects of pegloticase on renal function in patients with CKD stages 3 and 4, as well as the effects of renal dysfunction on pegloticase efficacy and safety.Patients with renal insufficiency were randomized to pegloticase 8 mg every 2 weeks (n = 42), pegloticase 8 mg every 4 weeks (n = 41), or placebo (n = 20) for 6 months as defined by the study protocols. Renal function was assessed by estimated glomerular filtration rate (eGFR). All patients completing the randomized trials could participate in an open-label extension study for a further 2.5 years. Uric acid response, the primary end point in the trials, was plasma uric acid <6.0 mg/dl for 80% of months 3 and 6.Mean eGFR in both pegloticase dosing cohorts remained constant over the randomized treatment phase and long-term open-label extension study. The number of patients achieving uric acid response was similar across CKD stages (32% stage 1, 23% stage 2, 35% stage 3, and 39% stage 4, respectively, P = 0.3). There was no difference in the pegloticase safety profile based on CKD stage.Pegloticase treatment does not impact eGFR in CKD patients and response to pegloticase is independent of CKD stage.Clinical trial identifier: NCT00325195.

Full Text

Duke Authors

Cited Authors

  • Yood, RA; Ottery, FD; Irish, W; Wolfson, M

Published Date

  • January 21, 2014

Published In

Volume / Issue

  • 7 /

Start / End Page

  • 54 -

PubMed ID

  • 24447425

Pubmed Central ID

  • 24447425

Electronic International Standard Serial Number (EISSN)

  • 1756-0500

International Standard Serial Number (ISSN)

  • 1756-0500

Digital Object Identifier (DOI)

  • 10.1186/1756-0500-7-54

Language

  • eng